Loading…
← CockpitCompetitor Analysis › 002262.SZ Jiangsu Nhwa Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A002262.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Chinese pharma company focused on central-nervous-system (CNS) drugs, including antidepressants and antipsychotics.

Momentum leader 93
Mkt cap
$3.48B
US dollars, full cap
Free float
55%
of shares outstanding
$/day
$27.8M
20-day average traded
Fwd P/E
19.6×
forward earnings
ROIC−WACC
+15.9 pp
WACC 5.0%
Hurdle
-14 pp
Req g minus delivered
Next earnings
127 days
25 Mar 2027
Close · CNYCN¥22.80
1D-0.5%
1W+2.3%
1M+5.0%
3M+3.0%
6M+8.1%
YTD-5.5%
1Y-5.7%
ATR %2.4%
52w lowhigh11.3% off high

What Jiangsu Nhwa Pharmaceutical does

Chinese pharma company focused on central-nervous-system (CNS) drugs, including antidepressants and antipsychotics.

Sells prescription drugs for the nervous system through hospitals, where government group-purchasing programmes press prices on older generics. Chinese rules restrict production of many psychotropic and anaesthetic drugs to licensed makers, which limits the number of competitors in parts of its range.

Products and services

  • Antidepressant/antipsychotic drugs
  • Other generics

Customers

  • Hospitals/psychiatric clinics

Where it sits in the supply chain

  • Health Care
  • Pharmaceuticals
  • CNS/psychiatric drugs

What could go right

  • Rising mental-health treatment demand in China

What could go wrong

  • Centralized procurement price pressure

Moat: narrow (regulatory licence, brand). Established CNS drug portfolio and physician relationships in a specialized therapeutic area.

Headquarters: Taizhou, Jiangsu, China · Employees: 6,003

Named competitors

Jiangsu Nhwa Pharmaceutical at a glance

Size Jiangsu Nhwa Pharmaceutical (002262.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $3.48B, the 702nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥22.80 on 18 Nov 2026.

Performance Over six months the shares gained 8.1%, against +3.4% for the median peer and -20.0% for the China market (cap-weighted) — 10th highest of 20 in its peer set.

Growth Revenue grew 3.2% over the last twelve months (peer median +9.4%); the operating margin is 18.9% (peer median 10.1%).

Valuation It trades at 19.6× forward earnings against a peer median of 16.8× (6th most expensive of 12).

Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -14 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 15.9 points above its cost of capital (5.0% WACC).

Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026002262.SZ 111Peer median 105
Six months, rebased to 100: Jiangsu Nhwa Pharmaceutical against the median of its 20 peers (local-currency closes).

Jiangsu Nhwa Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥6.22BCN¥5.85BCN¥5.63BCN¥4.99BCN¥4.25B
Revenue growth—+4%+13%+17%—
Gross profitCN¥4.38BCN¥4.04BCN¥3.99BCN¥3.53BCN¥3.16B
EBITDAn/aCN¥1.36BCN¥1.45BCN¥1.24BCN¥1.05B
Net incomeCN¥1.10BCN¥1.06BCN¥1.14BCN¥1.04BCN¥901M
Free cash flowCN¥579MCN¥687MCN¥512MCN¥677MCN¥566M
Capital expenditureCN¥490MCN¥437MCN¥450MCN¥374MCN¥328M
Total debtCN¥392MCN¥448MCN¥449MCN¥173MCN¥122M

Quarterly statements and history in the cockpit →

Jiangsu Nhwa Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-20%0%+20%+40%688180ARQTACUTAASSFZNWOCKPHARMAAMLXVRDN2096PPLPHARMA000739600521OGNSLSXENE6005111513TARS002262.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Jiangsu Nhwa Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%+60%0×50×100×150×ARQTACUTAASSFZN2096PPLPHARMA0007393320OGN1513002262.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Jiangsu Nhwa Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%200%ARQTWOCKPHARMA2096000739TARS002262.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Jiangsu Nhwa Pharmaceutical is the large dot.

Jiangsu Nhwa Pharmaceutical competitors and peer comparison

Head to head with its named competitors (002262.SZ vs 600276.SS vs 2186.HK vs 4578.T)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Jiangsu Nhwa Pharmaceutical 002262.SZ$3.48B+8%+3%19%19.6×-2.1%
Jiangsu Hengrui Pharmaceuticals 600276.SS$45.7B-13%+6%27%33.4×13.4%
Luye Pharma 2186.HK$736M-32%+3%18%7.1×-11.8%
Otsuka Hldgs 4578.T$39.9B+9%+11%18%16.8×1.6%

How Jiangsu Nhwa Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Jiangsu Nhwa Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure002262.SZPeer medianRank in peer set
1-month return+5.0%+2.6%10th highest of 21
6-month return+8.1%+3.4%10th highest of 20
Distance from 52-week high-11.3%-22.7%5th highest of 21
Revenue growth (TTM)+3.2%+9.4%6th lowest of 18
Operating margin18.9%10.1%4th highest of 16
Forward P/E19.6×16.8×6th most expensive of 12
Growth the price implies (Req g, 7 yrs)-2.1%0.6%6th least demanding of 11
Growth delivered (Del g)+12.0%+5.6%3rd highest of 11
Hurdle (Req g minus delivered)-14.1 pp-10.8 pp4th least demanding of 11
ROIC minus cost of capital+15.9 pp+3.7 pphighest of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Jiangsu Nhwa Pharmaceutical 002262.SZChina$3.48B+8%+3%19%19.6×-2.1%+12.0%
Shanghai Junshi Biosciences 688180.SSChina$3.48B-31%+29%-15%n/an/an/a
Arcutis Biotherapeutics ARQTUnited States$3.49B+35%+60%7%41.0×49.2%+367.3%
Acutaas Chemicals ACUTAAS.NSIndia$3.50B+38%+45%36%63.6×n/an/a
Siegfried SFZN.SWSwitzerland$3.51B-17%+4%16%16.8×n/an/a
Parabilis Medicines PBLSUnited States$3.52Bn/an/an/an/an/an/a
Wockhardt WOCKPHARMA.NSIndia$3.52B+25%+26%13%n/a58.0%+4.2%
Amylyx Pharmaceuticals AMLXUnited States$3.42B+93%+100%n/an/an/an/a
Viridian Therapeutics VRDNUnited States$3.42B+71%-63%-1,781%n/an/an/a
Simcere Pharmaceutical 2096.HKHong Kong$3.42B-5%+27%18%13.5×-3.4%+10.6%
Piramal Pharma PPLPHARMA.NSIndia$3.40B+38%+9%3%150.8×n/an/a
Apeloa Pharmaceutical 000739.SZChina$3.37B+17%-16%10%22.9×4.7%+4.5%
China Resources Pharmaceutical 3320.HKHong Kong$3.60B-7%+8%4%5.8×-4.9%+7.8%
Zhejiang Huahai Pharmaceutical 600521.SSChina$3.61B0%+10%12%20.1×6.4%+5.9%
Viking Therapeutics VKTXUnited States$3.34B-9%n/an/an/an/an/a
Organon & OGNUnited States$3.66B+3%-3%20%4.0×-4.1%-1.0%
SELLAS Life Sciences SLSUnited States$3.66B+100%n/an/an/an/an/a
Xenon Pharmaceuticals XENEUnited States$3.71B-31%-100%n/an/an/an/a
China National Medicines 600511.SSChina$3.26B+3%+3%4%10.5×-10.0%+5.4%
Livzon Pharmaceutical 1513.HKHong Kong$3.73B-9%-10%19%11.3×-7.0%+2.0%
Tarsus Pharmaceuticals TARSUnited States$3.74B+17%+86%-10%n/a34.7%+159.5%

Questions

Who are Jiangsu Nhwa Pharmaceutical's main competitors?
Named competitors: Jiangsu Hengrui Pharmaceuticals (600276.SS), Luye Pharma (2186.HK), Lundbeck (private or unlisted), Otsuka Holdings (4578.T). The cockpit's measured peer set (industry) also includes Shanghai Junshi Biosciences (688180.SS), Arcutis Biotherapeutics (ARQT), Acutaas Chemicals (ACUTAAS.NS), Siegfried (SFZN.SW), Parabilis Medicines (PBLS), Wockhardt (WOCKPHARMA.NS).
Is Jiangsu Nhwa Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 19.6× against a peer median of 16.8×, 6th most expensive of 12 in its peer set. For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -14 pp: the price already allows for a slowdown.
How has Jiangsu Nhwa Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned +8.1% against +3.4% for the median peer; over one year -5.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.